Cell & Gene Therapy Drug Delivery Devices Market by Products, Commercialized Drugs

Description

List of Tables

The Cell & Gene Therapy Drug Delivery Devices Market was valued at USD 1.08 billion in 2023, expected to reach USD 1.17 billion in 2024, and is projected to grow at a CAGR of 9.78%, to USD 2.08 billion by 2030.

The scope of the market for cell and gene therapy drug delivery devices focuses on innovative technologies that facilitate the targeted delivery of therapeutic agents to specific cells or genes to treat or modify genetic disorders and other major diseases. These devices are essential for improving the precision and efficiency of therapies and minimizing off-target effects, thereby maximizing therapeutic potential. Applications extend across oncology, rare genetic disorders, and immunological conditions, with key end-users including research institutes, hospitals, and biopharmaceutical companies. Growth is driven by the escalating adoption of cell and gene therapies, technological advancements in delivery systems, and increased funding and investments in genetic research. Opportunities emerge in the integration of artificial intelligence for personalization of therapies, development of non-viral delivery methods, and the collaboration between technology firms and biotech companies to create multi-functional delivery platforms. Strategic recommendations include partnerships for technology development, investing in emerging markets, and focus on patient-centric delivery solutions. However, the market faces challenges such as high costs, stringent regulatory requirements, and complex manufacturing processes, which can limit scalability and accessibility. The inherent complexity of genetic material handling and the need for specialized infrastructure further exacerbate these challenges. Areas ripe for innovation include the development of novel nanoparticles, lipid-based carriers, and biodegradable polymers designed to improve safety and efficacy. Additionally, the exploration of CRISPR-based delivery systems and advancements in microfluidic technology offer significant promise for the market's evolution. Innovation should address the optimization of delivery mechanisms, reduction of manufacturing costs, and enhancement of delivery precision. The market is characterized by rapid technological evolution and high competition, encouraging continual research and collaboration. Stakeholders must navigate regulatory landscapes carefully while fostering innovation that aligns with clinical needs and enhances therapeutic outcomes.

KEY MARKET STATISTICS
Base Year [2023]	USD 1.08 billion
Estimated Year [2024]	USD 1.17 billion
Forecast Year [2030]	USD 2.08 billion
CAGR (%)	9.78%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell & Gene Therapy Drug Delivery Devices Market

The Cell & Gene Therapy Drug Delivery Devices Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Rising number of chronic and genetic disorders
- Growing number of drug approvals for treatment of cellular and genetic disorders
- Increasing number of clinical trials and medical treatments requiring advanced drug delivery systems
Market Restraints
- High cost of drug delivery devices
Market Opportunities
- Advancements in nanotechnology and development of biomaterials
- Utilization of AI, ML, and sensor technologies for drug delivery
Market Challenges
- Complex regulatory challenges of genetic therapies and difficulties with approval of medical devices

Porter's Five Forces: A Strategic Tool for Navigating the Cell & Gene Therapy Drug Delivery Devices Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell & Gene Therapy Drug Delivery Devices Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell & Gene Therapy Drug Delivery Devices Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell & Gene Therapy Drug Delivery Devices Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell & Gene Therapy Drug Delivery Devices Market

A detailed market share analysis in the Cell & Gene Therapy Drug Delivery Devices Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell & Gene Therapy Drug Delivery Devices Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell & Gene Therapy Drug Delivery Devices Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cell & Gene Therapy Drug Delivery Devices Market

A strategic analysis of the Cell & Gene Therapy Drug Delivery Devices Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Drug Delivery Devices Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Bausch & Lomb Incorporated, Becton, Dickinson and Company, Bluebird bio, Inc., Castle Creek Biosciences, Inc. by Paragon Biosciences, LLC, Dendreon Pharmaceuticals LLC., Helixmith Co., Ltd., Kite Pharma, Inc. by Gilead, Kolon TissueGene, Inc., Novartis AG, Orchard Therapeutics, Pfizer, Inc., Renova Therapeutics, Spark Therapeutics, Inc., uniQure N.V., and Vericel Corporation.

Market Segmentation & Coverage

This research report categorizes the Cell & Gene Therapy Drug Delivery Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Products, market is studied across Extension Tube, Infusion Bags, Intravenous Catheter, Pre-Filled Syringe, Sterile Insulin Syringe, and Subretinal Injection Cannula.
Based on Commercialized Drugs, market is studied across Kymriah, Luxturna, Provenge, Strimvelis, Yescarta, and Zolgensma.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-5C6F41F5AF95

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising number of chronic and genetic disorders
  - 5.1.1.2. Growing number of drug approvals for treatment of cellular and genetic disorders
  - 5.1.1.3. Increasing number of clinical trials and medical treatments requiring advanced drug delivery systems
- 5.1.2. Restraints
  - 5.1.2.1. High cost of drug delivery devices
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in nanotechnology and development of biomaterials
  - 5.1.3.2. Utilization of AI, ML, and sensor technologies for drug delivery
- 5.1.4. Challenges
  - 5.1.4.1. Complex regulatory challenges of genetic therapies and difficulties with approval of medical devices
5.2. Market Segmentation Analysis
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Cell & Gene Therapy Drug Delivery Devices Market, by Products

6.1. Introduction
6.2. Extension Tube
6.3. Infusion Bags
6.4. Intravenous Catheter
6.5. Pre-Filled Syringe
6.6. Sterile Insulin Syringe
6.7. Subretinal Injection Cannula

7. Cell & Gene Therapy Drug Delivery Devices Market, by Commercialized Drugs

7.1. Introduction
7.2. Kymriah
7.3. Luxturna
7.4. Provenge
7.5. Strimvelis
7.6. Yescarta
7.7. Zolgensma

8. Americas Cell & Gene Therapy Drug Delivery Devices Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Cell & Gene Therapy Drug Delivery Devices Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Cell & Gene Therapy Drug Delivery Devices Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation

Companies Mentioned

1. Amgen Inc.
2. Bausch & Lomb Incorporated
3. Becton, Dickinson and Company
4. Bluebird bio, Inc.
5. Castle Creek Biosciences, Inc. by Paragon Biosciences, LLC
6. Dendreon Pharmaceuticals LLC.
7. Helixmith Co., Ltd.
8. Kite Pharma, Inc. by Gilead
9. Kolon TissueGene, Inc.
10. Novartis AG
11. Orchard Therapeutics
12. Pfizer, Inc.
13. Renova Therapeutics
14. Spark Therapeutics, Inc.
15. uniQure N.V.
16. Vericel Corporation